City of Hope to Present New Research at the American Association of Cancer Research (AACR) Annual Meeting 2024, Highlighting Promising Data on Prostate, Colorectal and Pancreatic Cancer

Studies focus on molecular profiling, CAR T cell therapies, early detection and artificial intelligence applications in cancer research

Researchers with City of Hope®, one of the largest cancer research and treatment organizations in the United States, will present new findings at the AACR Annual Meeting, which will take place April 5 to 10 in San Diego.

This year, City of Hope doctors and scientists will also present data during AACR’s Press Program and a clinical trials plenary session:

Additional data presentations include:

  • “Multi-omics characterization of molecular features and global-local genomic ancestry analysis of colorectal cancer in Hispanic-Latinos”

    Minisymposium session 3932: Monday, April 8, 2024, 3:35 to 3:50 p.m.

    To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S., City of Hope assistant professor, Department of Integrative Translational Sciences, and John D. Carpten, Ph.D., City of Hope's chief scientific officer, Irell & Manella Cancer Center Director's Distinguished Chair and Morgan & Helen Chu Director's Chair of the Beckman Research Institute, along with a team of researchers, searched for mutations in CRC tumors by utilizing molecular profiling technologies. Results yielded important insights into the molecular characterization of CRC tumors and the multifaceted clinical and genomic heterogeneity within Hispanic/Latino populations, as well as crucial information on CRC tumor heterogeneity and the tumor microenvironment.



  • “Microbiome modification impacts PSCA directed chimeric antigen receptor (CAR) T cell therapy for prostate cancer”

    Poster presentation 6676/7: Wednesday, April 10, 2024, 9 a.m. to 12:30 p.m.

    John Murad, Ph.D., a staff scientist in the laboratory of Saul J. Priceman, Ph.D., City of Hope associate professor, Department of Hematology & Hematopoietic Cell Transplantation, and colleagues developed methods to evaluate the impact of microbiome manipulation in the team’s established syngeneic PSCA+ prostate cancer mouse model. They found that the model was sensitive to microbiome modulation and that the use of patient-derived human fecal matter transfers can significantly impact PSCA-CAR T cell directed anti-tumor responses.

Late-Breaking Presentation

Symposiums and Educational Sessions

About City of Hope

City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHope™. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.